TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF ELI LILLY AND COMPANY

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2020–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	6	2
2025	—	8	2
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
TIBER CREEK GROUP	—	28
B HALL STRATEGIES, LLC	—	7

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	33
HOUSE OF REPRESENTATIVES	27
Executive Office of the President (EOP)	19
Commerce, Dept of (DOC)	4
Energy, Dept of	3

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	29
Health Issues	Health Issues	20
Copyright/Patent/Trademark	Copyright/Patent/Trademark	17
Trade (domestic/foreign)	Trade (domestic/foreign)	10
Pharmacy	Pharmacy	5
Budget/Appropriations	Budget/Appropriations	4
Immigration	Immigration	3
Energy/Nuclear	Energy/Nuclear	3
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	2

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 6509

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1096

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

Client expense: — · Firm income: $80,000

Matched citations: S.2658

Show 21 more cited filings

S. 3267119th Congress

ASAP Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to S. 3267 - ASAP Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 3267

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Client expense: — · Firm income: $80,000

Matched citations: S. 3794

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 6509

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2026 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1096

S. 2658119th Congress

Medication Affordability and Patent Integrity Act

2026 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

Client expense: — · Firm income: $80,000

Matched citations: S.2658

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).

Client expense: — · Firm income: $80,000

Matched citations: H.R. 6509

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2026 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2026 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1096

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 4231

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 6509

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1096

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Client expense: — · Firm income: $80,000

Matched citations: S. 1973

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding.

Client expense: — · Firm income: $80,000

Matched citations: H.R. 4231

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1096

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding.

Client expense: — · Firm income: $80,000

Matched citations: S. 1973

S. 1041119th Congress

Affordable Prescriptions for Patients Act

2025 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1041

S. 1096119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

2025 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 Preserve Access to Affordable Generics and Biosimilars Act.

Client expense: — · Firm income: $80,000

Matched citations: S. 1096

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2025 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Client expense: — · Firm income: $80,000

Matched citations: S. 1973

Source: Senate LDA

TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF ELI LILLY AND COMPANY — Lobbying Disclosure | Poliscope